دورية أكاديمية
أعرض في EDS

Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France

التفاصيل البيبلوغرافية
العنوان: Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France
المؤلفون: Dormoy, Alexandre, Haissaguerre, Magalie, Vitellius, Géraldine, Do Cao, Christine, Geslot, Aurore, Drui, Delphine, Lasolle, Hélène, Vieira-Pinto, Oceana, Salenave, Sylvie, François, Maud, Puerto, Marie, Boullay, Hélène Du, Mayer, Anne, Rod, Anne, Laurent, Claire, Chanson, Philippe, Reznik, Yves, Castinetti, Frédéric, Chabre, Olivier, Baudin, Eric, Raverot, Gérald, Tabarin, Antoine, Young, Jacques
المساهمون: Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris-Saclay, Hôpital Haut-Lévêque CHU Bordeaux, CHU Bordeaux, Hôpital Robert Debré, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), ITX-lab unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Hospices Civils de Lyon (HCL), Hôpital Robert Debré-Hôpital universitaire Robert Debré Reims (CHU Reims), Centre Hospitalier Métropole Savoie Chambéry, Centre Hospitalier Georges Renon Niort (CH Georges Renon Niort), AP-HP. Université Paris Saclay, Physiologie et physiopathologie endocriniennes (PHYSENDO), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Côte de Nacre CHU Caen, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital de la Conception CHU - APHM (LA CONCEPTION), Aix Marseille Université (AMU), Centre Hospitalier Universitaire CHU Grenoble (CHUGA), BioSanté (UMR BioSanté), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA), Département de médecine oncologique Gustave Roussy, Institut Gustave Roussy (IGR)
المصدر: ISSN: 0021-972X.
بيانات النشر: HAL CCSD
Endocrine Society
سنة النشر: 2023
مصطلحات موضوعية: Cushing syndrome, adrenal insufficiency, corticotropin, ectopic adrenocorticotropic hormone syndrome, hypokalemia, neuroendocrine tumors, osilodrostat, paraneoplastic Cushing syndrome, steroidogenesis inhibitors, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism
الوصف: International audience ; Abstract Context Prospective studies have demonstrated the efficacy of osilodrostat in Cushing disease. No study has evaluated osilodrostat in a series of patients with paraneoplastic Cushing syndrome/ectopic adrenocorticotropin syndrome (PNCS/EAS). Objective This work aimed to evaluate in France the real-world efficacy and safety of osilodrostat in patients with PNCS/EAS. Methods A total of 33 patients with PNCS/EAS with intense/severe hypercortisolism were involved in this retrospective, multicenter, real-world study. Patients received osilodrostat between May 2019 and March 2022 at a median initial dose (range) of 4 mg/day (1-60) and maximum dose, 20 mg/day (4-100), first under patient then cohort temporary authorizations and after marketing authorization. Regimens used titration (n = 6), block and replace (n = 16), or titration followed by block and replace (n = 11). Results In 11 patients receiving osilodrostat as first-line monotherapy, median 24-hour urinary free cortisol (24h-UFC) decreased dramatically (from 26 × upper limit of normal [ULN; 2.9-659] to 0.11 × ULN [0.08-14.9]; P < .001). In 9 of them, 24h-UFC normalization was achieved in 2 weeks (median). Thirteen additional patients were previously treated with classic steroidogenesis inhibitors but 10 of these 13 were not controlled. In these patients, osilodrostat monotherapy, used as second line, induced a significantly decreased of 24h-UFC (from 2.6 × ULN [1.1-144] to 0.22 × ULN [0.12-0.66]; P < .01). Nine additional patients received osilodrostat in combination with another anticortisolic drug, decreasing 24h-UFC from 11.8 × ULN (0.3-247) to 0.43 × ULN (0.33-2.4) (P < .01). In parallel, major clinical symptoms/comorbidities improved dramatically with improvement in blood pressure, hyperglycemia, and hypokalemia, allowing the discontinuation or dose reduction of patient treatments. Adrenal insufficiency (grade 3-4) was reported in 8 of 33 patients. Conclusion Osilodrostat is a rapidly efficient therapy for PNCS/EAS ...
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36470583; hal-04332295; https://universite-paris-saclay.hal.science/hal-04332295Test; https://universite-paris-saclay.hal.science/hal-04332295/documentTest; https://universite-paris-saclay.hal.science/hal-04332295/file/dgac691.pdfTest; PUBMED: 36470583; PUBMEDCENTRAL: PMC10188310
DOI: 10.1210/clinem/dgac691
الإتاحة: https://doi.org/10.1210/clinem/dgac691Test
https://universite-paris-saclay.hal.science/hal-04332295Test
https://universite-paris-saclay.hal.science/hal-04332295/documentTest
https://universite-paris-saclay.hal.science/hal-04332295/file/dgac691.pdfTest
حقوق: http://creativecommons.org/licenses/by-nc-ndTest/ ; info:eu-repo/semantics/OpenAccess
رقم الانضمام: edsbas.1DD365D7
قاعدة البيانات: BASE
ResultId 1
Header edsbas
BASE
edsbas.1DD365D7
975
3
Academic Journal
academicJournal
975.149597167969
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.1DD365D7&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://doi.org/10.1210/clinem/dgac691# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dormoy%2C+Alexandre%22&quot;&gt;Dormoy, Alexandre&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Haissaguerre%2C+Magalie%22&quot;&gt;Haissaguerre, Magalie&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Vitellius%2C+G&#233;raldine%22&quot;&gt;Vitellius, G&#233;raldine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Do+Cao%2C+Christine%22&quot;&gt;Do Cao, Christine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Geslot%2C+Aurore%22&quot;&gt;Geslot, Aurore&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Drui%2C+Delphine%22&quot;&gt;Drui, Delphine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lasolle%2C+H&#233;l&#232;ne%22&quot;&gt;Lasolle, H&#233;l&#232;ne&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Vieira-Pinto%2C+Oceana%22&quot;&gt;Vieira-Pinto, Oceana&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Salenave%2C+Sylvie%22&quot;&gt;Salenave, Sylvie&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Fran&#231;ois%2C+Maud%22&quot;&gt;Fran&#231;ois, Maud&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Puerto%2C+Marie%22&quot;&gt;Puerto, Marie&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Boullay%2C+H&#233;l&#232;ne+Du%22&quot;&gt;Boullay, H&#233;l&#232;ne Du&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mayer%2C+Anne%22&quot;&gt;Mayer, Anne&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Rod%2C+Anne%22&quot;&gt;Rod, Anne&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Laurent%2C+Claire%22&quot;&gt;Laurent, Claire&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Chanson%2C+Philippe%22&quot;&gt;Chanson, Philippe&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Reznik%2C+Yves%22&quot;&gt;Reznik, Yves&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Castinetti%2C+Fr&#233;d&#233;ric%22&quot;&gt;Castinetti, Fr&#233;d&#233;ric&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Chabre%2C+Olivier%22&quot;&gt;Chabre, Olivier&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Baudin%2C+Eric%22&quot;&gt;Baudin, Eric&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Raverot%2C+G&#233;rald%22&quot;&gt;Raverot, G&#233;rald&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Tabarin%2C+Antoine%22&quot;&gt;Tabarin, Antoine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Young%2C+Jacques%22&quot;&gt;Young, Jacques&lt;/searchLink&gt; )
Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => H&#244;pital Bic&#234;tre AP-HP, Le Kremlin-Bic&#234;tre&lt;br /&gt;Assistance publique - H&#244;pitaux de Paris (AP-HP) (AP-HP)&lt;br /&gt;Universit&#233; Paris-Saclay&lt;br /&gt;H&#244;pital Haut-L&#233;v&#234;que CHU Bordeaux&lt;br /&gt;CHU Bordeaux&lt;br /&gt;H&#244;pital Robert Debr&#233;&lt;br /&gt;Centre Hospitalier R&#233;gional Universitaire CHU Lille (CHRU Lille)&lt;br /&gt;Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)&lt;br /&gt;Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)&lt;br /&gt;ITX-lab unit&#233; de recherche de l&#39;institut du thorax UMR1087 UMR6291 (ITX-lab)&lt;br /&gt;Institut National de la Sant&#233; et de la Recherche M&#233;dicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Universit&#233; - UFR de M&#233;decine et des Techniques M&#233;dicales (Nantes Univ - UFR MEDECINE)&lt;br /&gt;Nantes Universit&#233; - p&#244;le Sant&#233;&lt;br /&gt;Nantes Universit&#233; (Nantes Univ)-Nantes Universit&#233; (Nantes Univ)-Nantes Universit&#233; - p&#244;le Sant&#233;&lt;br /&gt;Nantes Universit&#233; (Nantes Univ)-Nantes Universit&#233; (Nantes Univ)&lt;br /&gt;Hospices Civils de Lyon (HCL)&lt;br /&gt;H&#244;pital Robert Debr&#233;-H&#244;pital universitaire Robert Debr&#233; Reims (CHU Reims)&lt;br /&gt;Centre Hospitalier M&#233;tropole Savoie Chamb&#233;ry&lt;br /&gt;Centre Hospitalier Georges Renon Niort (CH Georges Renon Niort)&lt;br /&gt;AP-HP. Universit&#233; Paris Saclay&lt;br /&gt;Physiologie et physiopathologie endocriniennes (PHYSENDO)&lt;br /&gt;Institut National de la Sant&#233; et de la Recherche M&#233;dicale (INSERM)-Universit&#233; Paris-Saclay&lt;br /&gt;H&#244;pital C&#244;te de Nacre CHU Caen&lt;br /&gt;CHU Caen&lt;br /&gt;Normandie Universit&#233; (NU)-Tumoroth&#232;que de Caen Basse-Normandie (TCBN)-Normandie Universit&#233; (NU)-Tumoroth&#232;que de Caen Basse-Normandie (TCBN)&lt;br /&gt;H&#244;pital de la Conception CHU - APHM (LA CONCEPTION)&lt;br /&gt;Aix Marseille Universit&#233; (AMU)&lt;br /&gt;Centre Hospitalier Universitaire CHU Grenoble (CHUGA)&lt;br /&gt;BioSant&#233; (UMR BioSant&#233;)&lt;br /&gt;Institut National de la Sant&#233; et de la Recherche M&#233;dicale (INSERM)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG)&lt;br /&gt;Direction de Recherche Fondamentale (CEA) (DRF (CEA))&lt;br /&gt;Commissariat &#224; l&#39;&#233;nergie atomique et aux &#233;nergies alternatives (CEA)-Commissariat &#224; l&#39;&#233;nergie atomique et aux &#233;nergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA))&lt;br /&gt;Commissariat &#224; l&#39;&#233;nergie atomique et aux &#233;nergies alternatives (CEA)-Commissariat &#224; l&#39;&#233;nergie atomique et aux &#233;nergies alternatives (CEA)-Universit&#233; Grenoble Alpes (UGA)&lt;br /&gt;D&#233;partement de m&#233;decine oncologique Gustave Roussy&lt;br /&gt;Institut Gustave Roussy (IGR) )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => &lt;i&gt;ISSN: 0021-972X&lt;/i&gt;. )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => HAL CCSD&lt;br /&gt;Endocrine Society )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2023 )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cushing+syndrome%22&quot;&gt;Cushing syndrome&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22adrenal+insufficiency%22&quot;&gt;adrenal insufficiency&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22corticotropin%22&quot;&gt;corticotropin&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22ectopic+adrenocorticotropic+hormone+syndrome%22&quot;&gt;ectopic adrenocorticotropic hormone syndrome&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22hypokalemia%22&quot;&gt;hypokalemia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22neuroendocrine+tumors%22&quot;&gt;neuroendocrine tumors&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22osilodrostat%22&quot;&gt;osilodrostat&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22paraneoplastic+Cushing+syndrome%22&quot;&gt;paraneoplastic Cushing syndrome&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22steroidogenesis+inhibitors%22&quot;&gt;steroidogenesis inhibitors&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22[SDV%2EMHEP%2EEM]Life+Sciences+[q-bio]%2FHuman+health+and+pathology%2FEndocrinology+and+metabolism%22&quot;&gt;[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism&lt;/searchLink&gt; )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => International audience ; Abstract Context Prospective studies have demonstrated the efficacy of osilodrostat in Cushing disease. No study has evaluated osilodrostat in a series of patients with paraneoplastic Cushing syndrome/ectopic adrenocorticotropin syndrome (PNCS/EAS). Objective This work aimed to evaluate in France the real-world efficacy and safety of osilodrostat in patients with PNCS/EAS. Methods A total of 33 patients with PNCS/EAS with intense/severe hypercortisolism were involved in this retrospective, multicenter, real-world study. Patients received osilodrostat between May 2019 and March 2022 at a median initial dose (range) of 4 mg/day (1-60) and maximum dose, 20 mg/day (4-100), first under patient then cohort temporary authorizations and after marketing authorization. Regimens used titration (n = 6), block and replace (n = 16), or titration followed by block and replace (n = 11). Results In 11 patients receiving osilodrostat as first-line monotherapy, median 24-hour urinary free cortisol (24h-UFC) decreased dramatically (from 26 &#215; upper limit of normal [ULN; 2.9-659] to 0.11 &#215; ULN [0.08-14.9]; P &lt; .001). In 9 of them, 24h-UFC normalization was achieved in 2 weeks (median). Thirteen additional patients were previously treated with classic steroidogenesis inhibitors but 10 of these 13 were not controlled. In these patients, osilodrostat monotherapy, used as second line, induced a significantly decreased of 24h-UFC (from 2.6 &#215; ULN [1.1-144] to 0.22 &#215; ULN [0.12-0.66]; P &lt; .01). Nine additional patients received osilodrostat in combination with another anticortisolic drug, decreasing 24h-UFC from 11.8 &#215; ULN (0.3-247) to 0.43 &#215; ULN (0.33-2.4) (P &lt; .01). In parallel, major clinical symptoms/comorbidities improved dramatically with improvement in blood pressure, hyperglycemia, and hypokalemia, allowing the discontinuation or dose reduction of patient treatments. Adrenal insufficiency (grade 3-4) was reported in 8 of 33 patients. Conclusion Osilodrostat is a rapidly efficient therapy for PNCS/EAS ... )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => info:eu-repo/semantics/altIdentifier/pmid/36470583; hal-04332295; https://universite-paris-saclay.hal.science/hal-04332295; https://universite-paris-saclay.hal.science/hal-04332295/document; https://universite-paris-saclay.hal.science/hal-04332295/file/dgac691.pdf; PUBMED: 36470583; PUBMEDCENTRAL: PMC10188310 )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1210/clinem/dgac691 )
Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1210/clinem/dgac691&lt;br /&gt;https://universite-paris-saclay.hal.science/hal-04332295&lt;br /&gt;https://universite-paris-saclay.hal.science/hal-04332295/document&lt;br /&gt;https://universite-paris-saclay.hal.science/hal-04332295/file/dgac691.pdf )
Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => http://creativecommons.org/licenses/by-nc-nd/ ; info:eu-repo/semantics/OpenAccess )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.1DD365D7 )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1210/clinem/dgac691 ) ) [Languages] => Array ( [0] => Array ( [Text] => English ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Cushing syndrome [Type] => general ) [1] => Array ( [SubjectFull] => adrenal insufficiency [Type] => general ) [2] => Array ( [SubjectFull] => corticotropin [Type] => general ) [3] => Array ( [SubjectFull] => ectopic adrenocorticotropic hormone syndrome [Type] => general ) [4] => Array ( [SubjectFull] => hypokalemia [Type] => general ) [5] => Array ( [SubjectFull] => neuroendocrine tumors [Type] => general ) [6] => Array ( [SubjectFull] => osilodrostat [Type] => general ) [7] => Array ( [SubjectFull] => paraneoplastic Cushing syndrome [Type] => general ) [8] => Array ( [SubjectFull] => steroidogenesis inhibitors [Type] => general ) [9] => Array ( [SubjectFull] => [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Dormoy, Alexandre ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Haissaguerre, Magalie ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Vitellius, Géraldine ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Do Cao, Christine ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Geslot, Aurore ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Drui, Delphine ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Lasolle, Hélène ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Vieira-Pinto, Oceana ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Salenave, Sylvie ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => François, Maud ) ) ) [10] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Puerto, Marie ) ) ) [11] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Boullay, Hélène Du ) ) ) [12] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Mayer, Anne ) ) ) [13] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Rod, Anne ) ) ) [14] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Laurent, Claire ) ) ) [15] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Chanson, Philippe ) ) ) [16] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Reznik, Yves ) ) ) [17] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Castinetti, Frédéric ) ) ) [18] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Chabre, Olivier ) ) ) [19] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Baudin, Eric ) ) ) [20] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Raverot, Gérald ) ) ) [21] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Tabarin, Antoine ) ) ) [22] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Young, Jacques ) ) ) [23] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre ) ) ) [24] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP) ) ) ) [25] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Université Paris-Saclay ) ) ) [26] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hôpital Haut-Lévêque CHU Bordeaux ) ) ) [27] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => CHU Bordeaux ) ) ) [28] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hôpital Robert Debré ) ) ) [29] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille) ) ) ) [30] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Centre Hospitalier Universitaire de Toulouse (CHU Toulouse) ) ) ) [31] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes) ) ) ) [32] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => ITX-lab unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX-lab) ) ) ) [33] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE) ) ) ) [34] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Nantes Université - pôle Santé ) ) ) [35] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé ) ) ) [36] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ) ) ) ) [37] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hospices Civils de Lyon (HCL) ) ) ) [38] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hôpital Robert Debré-Hôpital universitaire Robert Debré Reims (CHU Reims) ) ) ) [39] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Centre Hospitalier Métropole Savoie Chambéry ) ) ) [40] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Centre Hospitalier Georges Renon Niort (CH Georges Renon Niort) ) ) ) [41] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => AP-HP. Université Paris Saclay ) ) ) [42] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Physiologie et physiopathologie endocriniennes (PHYSENDO) ) ) ) [43] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay ) ) ) [44] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hôpital Côte de Nacre CHU Caen ) ) ) [45] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => CHU Caen ) ) ) [46] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN) ) ) ) [47] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hôpital de la Conception CHU - APHM (LA CONCEPTION) ) ) ) [48] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Aix Marseille Université (AMU) ) ) ) [49] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Centre Hospitalier Universitaire CHU Grenoble (CHUGA) ) ) ) [50] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => BioSanté (UMR BioSanté) ) ) ) [51] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG) ) ) ) [52] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Direction de Recherche Fondamentale (CEA) (DRF (CEA)) ) ) ) [53] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)) ) ) ) [54] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA) ) ) ) [55] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Département de médecine oncologique Gustave Roussy ) ) ) [56] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Institut Gustave Roussy (IGR) ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 01 [Type] => published [Y] => 2023 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-locals [Value] => edsbas ) [1] => Array ( [Type] => issn-locals [Value] => edsbas.oa ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => ISSN: 0021-972X [Type] => main ) ) ) ) ) ) )
IllustrationInfo